SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC reduced its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 38.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 183,761 shares of the company's stock after selling 114,138 shares during the period. Nuveen Asset Management LLC owned about 0.25% of SpringWorks Therapeutics worth $6,639,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in SWTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of SpringWorks Therapeutics by 2.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,013 shares of the company's stock worth $1,591,000 after acquiring an additional 931 shares during the period. Integral Health Asset Management LLC bought a new stake in SpringWorks Therapeutics in the fourth quarter valued at approximately $3,613,000. Deutsche Bank AG lifted its holdings in SpringWorks Therapeutics by 47.5% in the fourth quarter. Deutsche Bank AG now owns 60,714 shares of the company's stock valued at $2,194,000 after buying an additional 19,540 shares during the period. Duquesne Family Office LLC lifted its position in shares of SpringWorks Therapeutics by 21.9% during the 4th quarter. Duquesne Family Office LLC now owns 859,694 shares of the company's stock valued at $31,061,000 after acquiring an additional 154,628 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in shares of SpringWorks Therapeutics during the fourth quarter worth approximately $3,099,000.

SpringWorks Therapeutics Stock Up 0.1%

NASDAQ SWTX traded up $0.05 on Tuesday, reaching $46.72. The company had a trading volume of 1,930,953 shares, compared to its average volume of 2,239,075. The firm's 50 day moving average price is $43.29 and its 200 day moving average price is $43.33. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $62.00. The stock has a market capitalization of $3.52 billion, a PE ratio of -13.43 and a beta of 0.77.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The firm had revenue of $49.09 million for the quarter, compared to analysts' expectations of $64.19 million. On average, research analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on SWTX. Wedbush reissued a "neutral" rating and set a $47.00 target price (down previously from $81.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. TD Cowen reaffirmed a "hold" rating and set a $47.00 target price (down previously from $66.00) on shares of SpringWorks Therapeutics in a report on Tuesday, April 29th. Evercore ISI lowered SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Cowen downgraded SpringWorks Therapeutics to a "hold" rating in a research report on Tuesday, April 29th. Finally, Barclays reaffirmed an "equal weight" rating and set a $47.00 target price (down previously from $63.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $52.57.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.